| Literature DB >> 31683881 |
Kei Nakajima1,2,3, Ryoko Higuchi4.
Abstract
BACKGROUND: Recently, we have shown that extremely high high-density lipoprotein cholesterol (HDL-C), which was observed mostly in heavy drinkers, was associated with the incidence of diabetes. However, the observed association was influenced by the consumption of alcohol. Furthermore, it is unknown whether impaired glucose metabolism exists in people with extremely high HDL-C, regardless of their alcohol consumption. Therefore, we addressed this issue in people who did not have a habit of drinking alcohol.Entities:
Keywords: HDL; HbA1c; extremely high; fasting plasma glucose; nondrinker
Year: 2019 PMID: 31683881 PMCID: PMC6912278 DOI: 10.3390/jcm8111825
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Characteristics of participants according to HDL-C category.
| HDL-C Category | 20–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | 80–89 | 90–99 | 100–109 | 110–119 | ≥120 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 239 | 6626 | 24,770 | 37,770 | 40,245 | 32,046 | 19,494 | 9732 | 3981 | 1383 | 748 | |
| s-Age (years) | 55.2 ± 10.9 | 54.7 ± 10.6 | 55.0 ± 10.6 | 55.7 ± 10.8 | 55.9 ± 10.8 | 56.1 ± 10.7 | 56.3 ± 10.4 | 56.5 ± 10.2 | 56.8 ± 9.9 | 57.4 ± 9.7 | 58.3 ± 9.6 |
| Women, | 26 | 1233 | 8138 | 20,586 | 29,659 | 27,233 | 17,622 | 8977 | 3758 | 1305 | 708 |
| BMI (kg/m2) | 24.9 ± 2.9 | 24.6 ± 2.8 | 24.0 ± 2.9 | 23.0 ± 3.0 | 21.9 ± 2.9 | 21.1 ± 2.7 | 20.5 ± 2.5 | 20.1 ± 2.4 | 19.8 ± 2.4 | 19.5 ± 2.2 | 19.5 ± 2.5 |
| SBP (mmHg) | 123 ± 17.4 | 123 ± 16.2 | 122 ± 16.7 | 121 ± 17.3 | 119 ± 17.4 | 118 ± 17.5 | 117 ± 17.5 | 117 ± 17.4 | 117 ± 17.6 | 117 ± 17.5 | 117 ± 17.6 |
| DBP (mmHg) | 75.8 ± 11.5 | 76.3 ± 11.1 | 75.7 ± 11.3 | 74.2 ± 11.4 | 72.4 ± 11.2 | 71.4 ± 11.1 | 70.9 ± 11.1 | 70.7 ± 10.9 | 70.6 ± 11.0 | 70.7 ± 10.9 | 71.1 ± 10.9 |
| HDL-C (mg/dL) | 27 ± 1.9 | 36 ± 2.4 | 45 ± 2.8 | 55 ± 2.9 | 64 ± 2.9 | 74 ± 2.9 | 84 ± 2.8 | 94 ± 2.8 | 104 ± 2.8 | 114 ± 2.8 | 130 ± 11.1 |
| LDL-C (mg/dL) | 105 ± 34 | 128 ± 34 | 137 ± 32 | 136 ± 33 | 132 ± 32 | 129 ± 31 | 128 ± 30 | 127 ± 30 | 127 ± 30 | 129 ± 31 | 125 ± 33 |
| TG, IQ | 236 | 169 | 125 | 96 | 78 | 68 | 63 | 59 | 56 | 56 | 55 |
| HbA1c (%) | 5.96 ± 0.60 a | 5.99 ± 0.54 a | 5.95 ± 0.48 a | 5.89 ± 0.43 a | 5.84 ± 0.37 a | 5.82 ± 0.33 a | 5.81 ± 0.32 | 5.81 ± 0.31 | 5.82 ± 0.30 | 5.83 ± 0.28 | 5.86 ± 0.29 a |
| High HbA1c, | 84 a | 2531 a | 8555 a | 11,224 a | 10,339 a | 7376 | 4302 | 2144 | 895 | 337 | 207 a |
| High HbA1c, | 73 a | 2021 a | 5478 a | 4761 a | 2613 | 1056 | 411 | 176 | 67 | 15 | 10 |
| High HbA1c, | 11 | 510 a | 3077 a | 6463 a | 7726 a | 6320 | 3891 | 1968 | 828 | 322 | 197 a |
| FPG (mg/dL) | 99.5 ± 20.1 a | 98.1 ± 15.7 a | 96.5 ± 14.0 a | 94.2 ± 12.5 a | 92.3 ± 11.1 a | 91.1 ± 10.0 a | 90.4 ± 9.6 | 90.6 ± 9.5 | 90.5 ± 9.4 | 90.6 ± 9.3 | 91.4 ± 10.2 |
| High FPG, | 38 a | 914 a | 2708 a | 2938 a | 2104 a | 1252 a | 617 | 302 | 127 | 49 | 41 |
| Pharmacotherapy for | 35 | 1071 | 3818 | 5244 | 4505 | 3130 | 1711 | 791 | 292 | 97 | 73 |
| CVD, | — b | 193 | 671 | 862 | 812 | 641 | 378 | 170 | 68 | 18 | 14 |
| Current smoking, | 109 | 2588 | 6771 | 6295 | 4194 | 2172 | 1001 | 381 | 148 | 46 | 20 |
| Habitual exercise, | 57 | 1509 | 6263 | 10,555 | 11,644 | 9609 | 6054 | 3227 | 1286 | 512 | 287 |
| Mild to moderate | 98 | 2418 | 10,104 | 16,781 | 18,949 | 15,873 | 10,067 | 5291 | 2171 | 780 | 434 |
a Statistically significant difference in HbA1c, high HbA1c, FPG, and high FPG using Dunnett’s test compared with the 80–89 mg/dL HDL-C group. Dunnett’s test was conducted after the case was numbered as 1 and non-case as 0. b Not expressed because of the small number (<10), which could affect participants’ confidentiality. c Habitual exercise to a light sweat for over 30 min per session, twice weekly. d Physical activity (walking, and so on) more than 1 h per day (available n = 175,044). BMI—Body mass index, SBP—Systolic blood pressure, DBP—Diastolic blood pressure, HDL-C—High-density lipoprotein cholesterol, LDL-C—Low-density lipoprotein cholesterol, TG—Triglyceride, IQ—interquartile range FPG—Fasting plasma glucose, CVD—Cardiovascular disease. High HbA1c—HbA1c ≥ 42 mmol/mol (≥6.0%); high FPG—FPG ≥ 110 mg/dL (6.1 mmol/L).
Odds ratios (95% confidence intervals) of HDL cholesterol (HDL-C) categories for high HbA1c and high fasting plasma glucose (FPG).
| HDL-C | 20–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | 80–89 | 90–99 | 100–109 | 110–119 | ≥120 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| High HbA1c | |||||||||||
| Total | |||||||||||
| Model 1 | 1.91 *** | 2.18 *** | 1.86 *** | 1.49 *** | 1.22 *** | 1.06 * | 1 (ref) | 1 | 1.02 | 1.14 * | 1.35 ** |
| (1.46–2.50) | (2.06–2.32) | (1.79–1.95) | (1.43–1.56) | (1.17–1.27) | (1.01–1.10) | (0.94–1.06) | (0.94–1.11) | (1.00–1.29) | (1.15–1.59) | ||
| Model 2 | 2.07 *** | 2.42 *** | 2.02 *** | 1.56 *** | 1.25 *** | 1.06 ** | 1 (ref) | 0.99 | 1.01 | 1.1 | 1.27 ** |
| (1.57–2.72) | (2.27–2.58) | (1.93–2.12) | (1.49–1.62) | (1.20–1.30) | (1.02–1.11) | (0.93–1.05) | (0.93–1.09) | (0.96–1.25) | (1.07–1.50) | ||
| Model 3 | 0.62 ** | 1.12 ** | 1.19 *** | 1.11*** | 1.04 * | 1 (ref) | 1.03 | 1.08 ** | 1.15 ** | 1.31 *** | 1.49 *** |
| (0.46–0.84) | (1.05–1.20) | (1.14–1.24) | (1.07–1.15) | (1.01–1.08) | (0.98–1.07) | (1.02–1.15) | (1.06–1.25) | (1.15–1.49) | (1.26–1.76) | ||
| Model 4 | 0.61 ** | 1.10 ** | 1.18 *** | 1.11 *** | 1.05 * | 1 (ref) | 1.02 | 1.07 ** | 1.14 ** | 1.29 *** | 1.46 *** |
| (0.46–0.82) | (1.03–1.18) | (1.13–1.24) | (1.07–1.16) | (1.01–1.09) | (0.98–1.07) | (1.02–1.14) | (1.05–1.24) | (1.13–1.46) | (1.24–1.73) | ||
| Men | |||||||||||
| Model 3 | 0.64 ** | 1.14 * | 1.16 ** | 1.09 * | 1.06 | 1 (ref) | 1.04 | 1.25 * | 1.77 ** | 1.02 | 1.19 |
| (0.47–0.89) | (1.03–1.26) | (1.07–1.26) | (1.00–1.18) | (0.97–1.15) | (0.91–1.19) | (1.04–1.51) | (1.30–2.40) | (0.57–1.84) | (0.56–2.49) | ||
| Model 4 | 0.65 ** | 1.14 ** | 1.17 ** | 1.09 * | 1.06 | 1 (ref) | 1.04 | 1.25 * | 1.76 ** | 1 | 1.18 |
| (0.47–0.89) | (1.03–1.26) | (1.08–1.27) | (1.01–1.18) | (0.98–1.16) | (0.91–1.19) | (1.03–1.51) | (1.30–2.39) | (0.56–1.80) | (0.56–2.49) | ||
| Women | |||||||||||
| Model 3 | 0.65 | 1.01 | 1.16 *** | 1.10 *** | 1.03 | 1 (ref) | 1.02 | 1.07 * | 1.12 ** | 1.33 *** | 1.51 *** |
| (0.27–1.58) | (0.88–1.14) | (1.09–1.23) | (1.05–1.15) | (0.99–1.07) | (0.98–1.07) | (1.01–1.14) | (1.03–1.22) | (1.16–1.51) | (1.28–1.79) | ||
| Model 4 | 0.65 | 1 | 1.16 *** | 1.10 *** | 1.03 | 1 (ref) | 1.02 | 1.07 * | 1.12 ** | 1.32 *** | 1.50 *** |
| (0.27–1.58) | (0.88–1.14) | (1.09–1.23) | (1.05–1.15) | (0.99–1.07) | (0.98–1.07) | (1.01–1.13) | (1.03–1.22) | (1.16–1.51) | (1.27–1.78) | ||
| High FPG | |||||||||||
| Total | |||||||||||
| Model 1 | 5.78 *** | 4.90 *** | 3.76 *** | 2.58 *** | 1.69 *** | 1.24 *** | 1 (ref) | 0.98 | 1.01 | 1.12 | 1.77 ** |
| (4.05–8.26) | (4.40–5.45) | (3.43–4.11) | (2.36–2.82) | (1.54–1.85) | (1.13–1.37) | (0.85–1.13) | (0.83–1.22) | (0.84–1.51) | (1.28–2.46) | ||
| Model 2 | 3.55 *** | 3.26 *** | 2.68 *** | 2.05 *** | 1.50 *** | 1.20 ** | 1 (ref) | 0.99 | 1.03 | 1.13 | 1.73 ** |
| (2.47–5.11) | (2.92–3.64) | (2.44–2.95) | (1.87–2.24) | (1.37–1.65) | (1.08–1.32) | (0.86–1.14) | (0.85–1.25) | (0.84–1.52) | (1.25–2.40) | ||
| Model 3 | 0.83 | 1.26 ** | 1.34 *** | 1.27 *** | 1.14 ** | 1.07 | 1 (ref) | 1.09 | 1.2 | 1.39 * | 2.04 *** |
| (0.56–1.24) | (1.11–1.42) | (1.21–1.48) | (1.16–1.40) | (1.04–1.26) | (0.97–1.18) | (0.94–1.25) | (0.99–1.46) | (1.03–1.87) | (1.47–2.84) | ||
*p < 0.05, ** p < 0.01, *** p < 0.0001. Model 1: Unadjusted. Model 2: Adjusted for age and sex. Model 3: Model 2 plus adjustment for the use of anti-hypertensive therapy, history of cardiovascular disease, and habitual exercise (≥30 min exercise per session, >2 times/week vs. less frequent exercise), body mass index, systolic blood pressure, triglyceride, and smoking status. Model 4: Model 3 plus adjustment for the combined effect of sex, body mass index, exercise, and smoking status. High HbA1c—HbA1c ≥ 42 mmol/mol (≥6.0%); high FPG—FPG ≥ 110 mg/dL (6.1 mmol/L).